128 related articles for article (PubMed ID: 30860160)
1. Antibodies to dengue, Zika,
Sookaromdee P; Wiwanitkit V
Neurol India; 2019; 67(1):335. PubMed ID: 30860160
[No Abstract] [Full Text] [Related]
2. Antibodies to Zika virus,
Baskar D; Amalnath D; Mandal J; Dhodapkar R; Vanathi K
Neurol India; 2018; 66(5):1324-1331. PubMed ID: 30232998
[TBL] [Abstract][Full Text] [Related]
3. [Campylobacter jejuni enteritis and Guillain-Barré syndrome].
Yuki N
Rinsho Byori; 1999 Aug; 47(8):713-8. PubMed ID: 10511801
[TBL] [Abstract][Full Text] [Related]
4. Zika virus and Guillain-Barré syndrome: Cause or association?
Kalita J; Misra UK
Neurol India; 2018; 66(5):1288-1289. PubMed ID: 30232987
[No Abstract] [Full Text] [Related]
5. Guillain-Barré syndrome caused by Zika virus: A wake-up call for India.
Garg RK; Jain A; Rizvi I
Neurol India; 2018; 66(5):1290-1292. PubMed ID: 30232988
[No Abstract] [Full Text] [Related]
6. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders.
Enders U; Karch H; Toyka KV; Michels M; Zielasek J; Pette M; Heesemann J; Hartung HP
Ann Neurol; 1993 Aug; 34(2):136-44. PubMed ID: 8338338
[TBL] [Abstract][Full Text] [Related]
7. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barré syndrome?
Berciano J; Illa I
Neurology; 2005 Feb; 64(4):766-7; author reply 766-7. PubMed ID: 15728323
[No Abstract] [Full Text] [Related]
8. Anti-ganglioside antibodies in patients with Zika virus infection-associated Guillain-Barré Syndrome in Brazil.
Rivera-Correa J; de Siqueira IC; Mota S; do Rosário MS; Pereira de Jesus PA; Alcantara LCJ; Ernst JD; Rodriguez A
PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007695. PubMed ID: 31527907
[TBL] [Abstract][Full Text] [Related]
9. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan.
Ogawara K; Kuwabara S; Mori M; Hattori T; Koga M; Yuki N
Ann Neurol; 2000 Oct; 48(4):624-31. PubMed ID: 11026446
[TBL] [Abstract][Full Text] [Related]
10. Anti-ganglioside antibodies in patients with Guillain-Barré syndrome and Campylobacter jejuni infection.
Rees JH; Gregson NA; Hughes RA
J Infect Dis; 1995 Aug; 172(2):605-6. PubMed ID: 7622918
[No Abstract] [Full Text] [Related]
11. The relationship of Campylobacter jejuni infection and the development of Guillain-Barré syndrome.
Tsang RS
Curr Opin Infect Dis; 2002 Jun; 15(3):221-8. PubMed ID: 12015454
[TBL] [Abstract][Full Text] [Related]
12. Recognition characteristics of monoclonal antibodies that are cross-reactive with gangliosides and lipooligosaccharide from Campylobacter jejuni strains associated with Guillain-Barré and Fisher syndromes.
Houliston RS; Yuki N; Hirama T; Khieu NH; Brisson JR; Gilbert M; Jarrell HC
Biochemistry; 2007 Jan; 46(1):36-44. PubMed ID: 17198373
[TBL] [Abstract][Full Text] [Related]
13. [A case of Guillain-Barré syndrome after Campylobacter jejuni enterocolitis: anti-ganglioside antibody levels with or without Guillain-Barré syndrome].
Watanabe H; Shindo K; Nakamura Y; Nagamatsu M; Shiozawa Z; Kusunoki S
Rinsho Shinkeigaku; 2001 Sep; 41(9):625-7. PubMed ID: 11968750
[TBL] [Abstract][Full Text] [Related]
14. Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits.
Ang CW; De Klerk MA; Endtz HP; Jacobs BC; Laman JD; van der Meché FG; van Doorn PA
Infect Immun; 2001 Apr; 69(4):2462-9. PubMed ID: 11254608
[TBL] [Abstract][Full Text] [Related]
15. Antibodies to ganglioside complexes in Guillain-Barré syndrome: clinical correlates, fine specificity and complement activation.
Notturno F; Luciani M; Caporale CM; Ciarelli A; Uncini A
Int J Immunopathol Pharmacol; 2009; 22(2):437-45. PubMed ID: 19505396
[TBL] [Abstract][Full Text] [Related]
16. Campylobacter infections, Guillain-Barré syndrome, and parenteral gangliosides.
Callegaro L; Jack DB; Samson JC
Lancet; 1991 Mar; 337(8744):789. PubMed ID: 1672406
[No Abstract] [Full Text] [Related]
17. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barre syndrome?
Kuwabara S; Ogawara K; Misawa S; Koga M; Mori M; Hiraga A; Kanesaka T; Hattori T; Yuki N
Neurology; 2004 Aug; 63(3):529-33. PubMed ID: 15304587
[TBL] [Abstract][Full Text] [Related]
18. Is Campylobacter lipopolysaccharide bearing a GD3 epitope essential for the pathogenesis of Guillain-Barré syndrome?
Yuki N; Koga M; Hirata K
Acta Neurol Scand; 2000 Aug; 102(2):132-4. PubMed ID: 10949532
[TBL] [Abstract][Full Text] [Related]
19. Origin of ganglioside complex antibodies in Guillain-Barré syndrome.
Kuijf ML; Godschalk PC; Gilbert M; Endtz HP; Tio-Gillen AP; Ang CW; van Doorn PA; Jacobs BC
J Neuroimmunol; 2007 Aug; 188(1-2):69-73. PubMed ID: 17604126
[TBL] [Abstract][Full Text] [Related]
20. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome.
Jacobs BC; Hazenberg MP; van Doorn PA; Endtz HP; van der Meché FG
J Infect Dis; 1997 Mar; 175(3):729-33. PubMed ID: 9041356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
